REPLIGEN CORP (RGEN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RGEN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | Senior Advisor, Warburg Pincus; Director | 60 | ["Public Company Board/CEO", "Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "over 30 years of industry experience", "served as President and CEO of bioTheranostics", "served as President, Global Commercial Operations at Life Technologies", "Vice President, Manufacturing and General Manager at Biogen", "Senior Project Engineer, Vaccine Technology at Merck & Co., Inc.", "Senior Advisor at Warburg Pincus since 2020", "M.S. in Chemical Engineering from the University of California, Berkeley", "engineering degree from Ecole Sup\u00e9rieure de Physique et Chimie Industrielles, Paris", "extensive experience in the bioprocessing field", "large scale biologics manufacturing", "commercialization of consumables used in bioprocessing", "strategy and merger and acquisitions"] | ["Nominating & Corporate Governance"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LAB | Director | 55 | [] | [] | 2021 |
Biography sourced from the proxy statement filing.
Member of the Compensation Committee. The Board has determined that Mr. Barthelemy is independent within the meaning of the SEC and Nasdaq's director independence standards.